Biomarker Profiling for Head and Neck Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
The trial aims to better understand head and neck squamous cell carcinoma (HNSCC) by studying molecular biomarkers (unique biological indicators) in patients' blood and tissue during their regular treatment. It is non-interventional, meaning participants will receive their standard care without additional experimental treatments. Those with metastatic or recurring HNSCC, who are starting a specific type of therapy (anti-PD1 or PDL1 immunotherapy) and can provide a tumor sample, are a good fit. The goal is to gather insights that might help improve future treatment strategies. As an unphased trial, this study allows patients to contribute to research that could enhance future treatment options without altering their current care plan.
Why are researchers excited about this trial?
Researchers are excited about this trial because it focuses on a novel approach using multi-omic biomarker profiling in patients with Head & Neck Squamous Cell Carcinoma (HNSCC). Unlike traditional treatments such as surgery, radiation, and chemotherapy, which primarily aim to remove or destroy cancer cells, this study aims to understand the molecular landscape of the disease. By examining a wide array of biological markers, researchers hope to identify unique patterns that could lead to more personalized and effective treatment strategies. This approach has the potential to revolutionize how we predict treatment responses and tailor therapies to individual patients, ultimately improving outcomes and reducing unnecessary side effects.
Who Is on the Research Team?
Virginia Rhodes, MD
Principal Investigator
Tempus AI, Inc.
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Biomarker Profiling
Participants undergo tissue and blood-based molecular biomarker profiling during their standard of care treatment
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Find a Clinic Near You
Who Is Running the Clinical Trial?
Tempus Labs
Lead Sponsor
Tempus AI
Lead Sponsor
AstraZeneca
Industry Sponsor
Sir Pascal Soriot
AstraZeneca
Chief Executive Officer since 2012
Veterinary Medicine from École nationale vétérinaire d'Alfort, MBA from HEC Paris
Dr. Cristian Massacesi
AstraZeneca
Chief Medical Officer since 2021
MD from Marche Polytechnic University, Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology
Pascal Soriot
AstraZeneca
Chief Executive Officer since 2012
Veterinary Medicine from École nationale vétérinaire d'Alfort, MBA from HEC Paris
Cristian Massacesi
AstraZeneca
Chief Medical Officer since 2021
MD from Marche Polytechnic University, Medical Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.